Vor Biopharma (VOR) Preferred Stock Liabilities (2020)

Name: Vor Biopharma (VOR) Preferred Stock Liabilities (2020) | Business Quant
Creator: Business Quant

Vor Biopharma (VOR) reported Preferred Stock Liabilities of $42.8 million for Q4 2020, down 33.71% on a QoQ basis from $64.5 million in Q3 2020.

Vor Biopharma (VOR) has 1 years of Preferred Stock Liabilities data on file, last reported at $42.8 million in Q4 2020.

Quarterly Preferred Stock Liabilities changed N/A year-over-year to $42.8 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $42.8 million (changed N/A YoY) and the FY2020 annual result came in at $42.8 million, changed N/A from the prior year.
Preferred Stock Liabilities declined to $42.8 million in Q4 2020 per VOR's latest filing, from $64.5 million in the prior quarter.
Across five years, Preferred Stock Liabilities topped out at $64.5 million in Q3 2020 and bottomed at $2000.0 in Q2 2020.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Quantum Biopharma	961,148.99 Bn	961,148.98 Bn	-	-
2	Alterity Therapeutics	744,933.29 Bn	744,933.26 Bn	-	-
3	Legend Biotech	2,540.00 Bn	2,539.71 Bn	242.10 Mn	-
4	Nanobiotix	2,199.85 Bn	2,199.78 Bn	-	-
5	Akari Therapeutics	1,635.88 Bn	1,635.88 Bn	-	-
6	Vertex Pharmaceuticals	111.32 Bn	104.07 Bn	2.59 Bn	-
7	Evaxion A	62.56 Bn	62.54 Bn	-	-
8	Regeneron Pharmaceuticals	62.55 Bn	53.79 Bn	3.31 Bn	-
9	Alnylam Pharmaceuticals	39.57 Bn	36.56 Bn	959.66 Mn	-
10	Vor Biopharma	628.83 Mn	628.83 Mn	-	-

Download Data 🔒